This HTML5 document contains 133 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
wdthttp://www.wikidata.org/prop/direct/
wdtnhttp://www.wikidata.org/prop/direct-normalized/
schemahttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
rdfshttp://www.w3.org/2000/01/rdf-schema#
wikibasehttp://wikiba.se/ontology#
phttp://www.wikidata.org/prop/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n8http://dx.doi.org/10.1111/
n11http://rdf.ncbi.nlm.nih.gov/pubchem/reference/
xsdhhttp://www.w3.org/2001/XMLSchema#
wdshttp://www.wikidata.org/entity/statement/
wdhttp://www.wikidata.org/entity/

Statements

Subject Item
wd:Q46718321
rdf:type
wikibase:Item
schema:description
artículu científicu artigo científico 2005 nî lūn-bûn научна статия article scientifique επιστημονικό άρθρο 2005年學術文章 vědecký článek scientific article published in October 2005 bài báo khoa học vetenskaplig artikel artikull shkencor artykuł naukowy научни чланак 2005年學術文章 article científic 2005年の論文 наукова стаття, опублікована в жовтні 2005 2005年学术文章 wissenschaftlicher Artikel מאמר מדעי artikel ilmiah vedecký článok tudományos cikk 2005年學術文章 artigo científico научная статья 2005년 논문 2005年學術文章 vitskapeleg artikkel научни чланак scientific article published in October 2005 article scientific artikulong pang-agham articolo scientifico bilimsel makale naučni članak مقالة علمية نشرت في أكتوبر 2005 2005年学术文章 artículo científico publicado en 2005 บทความทางวิทยาศาสตร์ vitenskapelig artikkel 2005年学术文章 2005年学术文章 videnskabelig artikel სამეცნიერო სტატია artigo científico мақолаи илмӣ 2005年学术文章 2005年学术文章 scienca artikolo wetenschappelijk artikel articol științific scientific article published in October 2005 tieteellinen artikkeli অক্টোবর ২০০৫-এ প্রকাশিত বৈজ্ঞানিক নিবন্ধ teaduslik artikkel 2005年學術文章
p:P577
wds:Q46718321-E2BD2585-F13F-4247-ABA0-8BBACD15CEB0
wdt:P577
2005-10-01T00:00:00Z
p:P407
wds:Q46718321-D04A7A81-5CDE-4587-B150-3FAFF4824CDC
wdt:P407
wd:Q1860
p:P2860
wds:Q46718321-1539DA8B-4C3C-4767-934D-28EBB911698C wds:Q46718321-24305EB6-BD01-4A96-9575-EFFDCEBF7FDD wds:Q46718321-27850132-2B3A-44B4-9201-2AE2226A113F wds:Q46718321-0F3E376D-A1E7-48DE-934E-DC7BA68E75EA wds:Q46718321-13A9BB3A-5769-432C-9751-7D54B9BF99F5 wds:Q46718321-5C83DE94-74C7-41B6-8268-A3F347CA560F wds:Q46718321-6A48A62D-B401-4137-9489-8DD1B013A510 wds:Q46718321-74C3D5BB-5545-4DB5-A13E-06A339DE90DC wds:Q46718321-346FDFD7-9142-4D47-9212-06D362B6DFD3 wds:Q46718321-4E0054E8-5F83-41B4-834B-F03F77D2FACE wds:Q46718321-D48BBD94-7455-48B1-92E9-093B451FAC0D wds:Q46718321-D61247BF-42EC-4D92-9C6F-D5FD8919F342 wds:Q46718321-87E900D7-31B1-48BA-88EF-036F8DDA1E5B wds:Q46718321-A95F6C2F-FAD9-466B-B406-F65A57D1491A wds:Q46718321-CE5B984D-535C-4119-8206-16EDD3783330 wds:Q46718321-EB43C7DD-0FD8-4FAD-8A97-C3BA9BE0D576 wds:Q46718321-F5AA77BD-2D8B-458E-BBB1-E169C6CB792B wds:Q46718321-F8F21624-F144-4EBF-AD9D-6E14E0472D48 wds:Q46718321-E440D7C2-F50C-47E3-BA8C-C1C9985229E9 wds:Q46718321-E882CF9C-E712-4802-9D6B-889287B63646 wds:Q46718321-E946167F-5A21-44BE-BE41-049335BD231F
wdt:P2860
wd:Q45069566 wd:Q46460428 wd:Q46137937 wd:Q44730910 wd:Q28348017 wd:Q46427077 wd:Q45746648 wd:Q42162478 wd:Q44467256 wd:Q34504256 wd:Q45251617 wd:Q39658037 wd:Q34534235 wd:Q44497774 wd:Q33927160 wd:Q34136595 wd:Q43451102 wd:Q44577731 wd:Q45192164 wd:Q44709328 wd:Q46531630
p:P2093
wds:Q46718321-299631D9-EAB4-4F5B-8ABC-5DF8126BF60B
wdt:P2093
Ormerod AD
rdfs:label
Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?
skos:prefLabel
Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?
schema:name
Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern? Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?
p:P1476
wds:Q46718321-0A21D418-A70C-4397-9872-A9B810F4348E
wdt:P1476
Topical tacrolimus and pimecrolimus and the risk of cancer: how much cause for concern?
p:P304
wds:Q46718321-0AD8579E-D1FA-4500-812D-342C6E1E10F1
wdt:P304
701-705
p:P31
wds:Q46718321-ec60705f-fae9-462e-8e8f-4a34c958c88d wds:Q46718321-7039DCEE-0EC1-43A0-8C47-F2D4BB854876
wdt:P31
wd:Q7318358 wd:Q13442814
p:P698
wds:Q46718321-0B6FAD96-666F-4F85-8A28-88769900C97F
wdtn:P698
n11:16181449
wdt:P698
16181449
p:P1433
wds:Q46718321-1D07CEF0-89F0-4041-A6DA-58F7CC87D9CE
wdt:P1433
wd:Q4970191
p:P433
wds:Q46718321-E827401F-BEBA-42F4-9230-A63685B865E3
p:P478
wds:Q46718321-C56918F0-19E0-47D3-B96C-7600092F5C3B
wdt:P433
4
wdt:P478
153
p:P356
wds:Q46718321-394053EA-D6B1-4BFA-8BD4-98D8C88BA211
wdtn:P356
n8:J.1365-2133.2005.06899.X
wdt:P356
10.1111/J.1365-2133.2005.06899.X